Estrogens bind to two nuclear estrogen receptor (ER) subtypes, ERa and ERb, which are expressed in differing amounts in various tissues. The endogenous estrogen, 17b-estradiol (E2), binds to both subtypes with nearly equal affinity and is the prototypical agonist. Selective estrogen receptor modulators (SERMs) may bind to both subtypes with equivalent affinities but have agonist activities in some tissues while having antagonist activities in others. In the present study, we demonstrate that the first reported endogenous SERM, 27-hydroxycholesterol (27-OHC), binds preferentially (.100-fold) to ERb over ERa. Furthermore, 27-OHC is not able to fully compete with E2 binding, suggesting the two may bind at different sites. We provide an allosteric ternary complex model for the simultaneous binding of 27-OHC and E2 to ERb, which accurately describes the binding data we have observed. We conclude that 27-OHC is a negative allosteric modifier of E2 binding, with an inhibitor constantof 50 nM and cooperativity factor (a) of 0.036. We also propose an in silico threedimensional model of the simultaneous binding to guide future experiments. Further study of this unique binding model may allow for the discovery of novel ERb-selective ligands and potentially explain the lack of effectiveness of ERb-selective agonists in humans vs preclinical models.
strogens exert diverse actions on distinct target tissues. The classic actions of estrogens are mediated by two nuclear estrogen receptor (ER) subtypes, ERa and ERb (1) (2) (3) (4) . Knockout studies in rodents have shown that the ERs are important for the proper function of reproductive tissues (5, 6) . These studies, along with others using ER-selective ligands, have also demonstrated important roles for the ERs in the bone, cardiovascular system, breast, prostate, brain, immune system, and inflammatory processes (4) (5) (6) (7) (8) (9) (10) (11) . In tissues where ERa and ERb are both expressed, they often have opposing roles. ERa is often implicated in the stimulation of proliferation and inflammation, whereas ERb inhibits these processes (10) (11) (12) (13) (14) . Several exogenous ERb-selective agonists with antiproliferative and anti-inflammatory properties have been discovered and/or synthesized (10, 11, 15) . Another class of molecules, known as selective estrogen receptor modulators (SERMs), has similar affinities for both receptors but mixed agonist/antagonist properties, which are tissue, cell, and promoter dependent (16) . Multiple exogenous SERMs have been tested clinically, for example, for their ability to have positive effects similar to those of hormone replacement therapy in postmenopausal women, while attempting to avoid the side effects observed with hormone replacement therapy in the Women's Health Initiative study (17) (18) (19) (20) . Interestingly, the oxysterol, 27-hydroxycholesterol (27-OHC), has been identified as the first endogenous SERM (21) (22) (23) (24) .
27-OHC is the most abundant oxysterol in circulation, with a concentration of 150 to 730 nM (10% in an unesterified form) found in normal adult human serum (25) (26) (27) . 27-OHC is synthesized, from cholesterol, by the cytochrome p450 enzyme CYP27A1 and metabolized by CYP7B1. In humans, mutations in CYP27A1 cause the autosomal-recessive disease cerebrotendinous xanthomatosis (28) (29) (30) . The symptoms of this disease include brain and tendon xanthomas, dementia, epileptic seizures, mental retardation, and premature atherosclerosis. CYP7B1 mutations in humans result in the autosomal-recessive disease spastic paraplegia type 5 (31) (32) (33) . The most common symptoms of this disease are weakness and spasticity of the lower limbs. At least two cases of liver failure in infants have also been associated with mutations in CYP7B1 (34, 35). 27-OHC is an agonist for both liver X receptor (LXR) subtypes, LXRa and LXRb, which regulate cholesterol and fatty acid homeostasis (36) . As a SERM, 27-OHC acts as an ER agonist in MCF7 breast cancer cells and as an antagonist in the bone and vasculature (21) (22) (23) . Although the transcriptional activity of 27-OHC has recently been under investigation by many laboratories, the details of ER binding have not. In this report, we demonstrate the binding selectivity of 27-OHC for ERb over ERa and present an allosteric binding model for ERb.
Materials and Methods

Reagents
Tritiated 17b-estradiol ( 3 H-E2) was purchased from American Radiolabeled Chemicals (St. Louis, MO) and PerkinElmer (Waltham, MA). 17b-estradiol (E2) was purchased from SigmaAldrich (St. Louis, MO). 27-OHC and additional oxysterols were purchased from Avanti Polar Lipids (Alabaster, AL). Purified human full-length recombinant ERa (P2187) and ERb (P2466) proteins (PanVera) were purchased from Invitrogen/Life Technologies (Grand Island, NY). ICI 182,780 was a gift from Dr. Rex Hess (University of Illinois, Urbana-Champaign). For critical micelle concentration assays, 1-(2-pyridylazo)-2-naphthol (PAN) was purchased from Santa Cruz Biotechnology (Santa Cruz, CA), and absorbance at 470 nm was determined by following the methods of Furton and Norelus (37) using Synergy 2 (Biotek, Winooski, VT).
In vitro transcription/translation
Human ERa and ERb proteins were synthesized by using the in vitro rabbit reticulocyte lysate coupled transcription/translation (TnT) kit from Promega (Madison, WI). PCDNA3.1 vectors containing the ERs were incubated with the components of the kit, including the T7-polymerase, and incubated for 90 minutes at 30°C; they were then separated into aliquots, frozen, and stored at 220°C.
Competitive binding assays
Initial experiments were performed with TnT translation mixes, diluted to a final concentration of 1% volume-to-volume ratio in a buffer containing 10 mM Tris, 1 mM EDTA, and 10% volume-to-volume ratio glycerol (reagents from Fisher Scientific, Fairlawn, NJ). 3 H-E2 was added to a final concentration of 1 nM in these assays. Final experiments were performed with PanVera purified ERs, diluted to 0.3-0.5 nM in the same buffer as the TnTderived ER protein with the addition of 1 mM EGTA (SigmaAldrich), 1 mM phenylmethanesulfonyl fluoride (Sigma-Aldrich), 1 mM dithiothreitol (Fisher Scientific), and 0.01% weight-tovolume ratio bovine serum albumin (Fisher Scientific). 3 H-E2 was added to a final concentration of 3 nM in these assays. All assays were done on ice and incubated overnight at 4°C. Separation of free and bound ligand was done via addition of dextran-coated charcoal (DCC) at a final concentration of 1% weight-to-volume ratio. DCC was a mixture of 10% weightto-weight ratio dextran (Sigma-Aldrich) to activated charcoal powder (Sigma-Aldrich) in a final volume of assay buffer, yielding a 5% weight-to-volume ratio. DCC was incubated for 15 minutes with shaking every 5 minutes, followed by centrifugation for 10 minutes. The supernatant was removed and added to Scintisafe 30% scintillation cocktail (Fisher Scientific), vortexed, and measured on a MicroBeta Trilux (PerkinElmer) or Beckman scintillation counter (Beckman Coulter, Brea, CA).
Luciferase assays
Ishikawa uterine cancer cells were passaged in Eagle minimal essential medium (Sigma-Aldrich) supplemented with 10% fetal bovine serum and maintained at 37°C in the presence of 5% CO 2 . Cells were removed from flasks with trypsin and plated at 5 3 10 4 cells per well in 24-well plates, or 8 3 10 3 cells perwell in 96-well plates, for 18 to 24 hours in phenol red free Eagle minimal essential medium (Sigma-Aldrich) supplemented with DCCstripped 10% fetal bovine serum. Cells were then transfected with the vitellogenin estrogen response element luciferase reporter plasmid, the SV40-renilla expression plasmid as an internal control, and either the ERa or the ERb expression plasmid and incubated for 18 to 24 hours. Cells were treated with compounds for an additional 18 to 24 hours and then lysed. Luciferase and renilla activity were measured on a Biotek Synergy 2 plate reader using the Stop & Glo Dual Luciferase Kit from Promega.
Statistical analysis and in silico data
Nonlinear regressions, response and binding parameter determinations, and statistical analyses were performed by using Prism 6.0 (GraphPad, La Jolla, CA). The one-site competitive binding calculations in GraphPad software use the Cheng-Prusoff equation (38) . The allosteric binding parameter calculations use equation 6 from Christopoulos and Kenakin (39) , and additional information is available at https:// www.graphpad.com/guides/prism/7/curve-fitting/index.htm? reg_allosteric_competition.htm. Ligand docking was performed by using Rosetta Ligand on the Rosetta Online Server that Includes Everyone (40, 41) . Three-dimensional (3D) conformers of 27-OHC were created by using Frog2 version 2.14 (42). The top 10 models from each docking attempt were evaluated, and publication images were generated by using UCSF Chimera (UCSF Resource for Biocomputing, Visualization, and Informatics, San Francisco, CA) (43).
Results
One-site competitive binding analysis
Using a competitive radioligand binding assay, we measured the ability of 27-OHC to bind to the ERs.
Concentrations of receptor and
3 H-E2 were used that kept the specific binding to ,15% of the total radioligand concentration to prevent receptor-induced ligand depletion. We chose to use two different sources of receptor in preliminary experiments to rule out the possibility of source-specific results. Data shown are with the purified ERs because this allowed us to be consistent with receptor concentration. Half maximal inhibitory concentrations (IC50s) and inhibitor constant (Ki) values were obtained via analysis with Prism 6.0 software (GraphPad) by using the formula for one-site competitive binding.
27-OHC bound to ERb, but not ERa, in the presence of 3 nM 3 H-E2 [ Fig. 1 Fig. 1(A) ]. Also of note was that the saturating concentrations of 24(S)-OHC inhibited the binding of 3nM 3 H-E2 by only 50%.
Inhibition of ER transcriptional activity by oxysterols
We used an in vitro luciferase transcription assay to screen additional oxysterols for their ability to interact with the ERs selectively and similarly to 27-OHC in the presence of E2 in the Ishikawa uterine cancer cell line. Ishikawa uterine cancer cells were transfected with the vitellogenin estrogen response element-driven luciferase reporter, a renilla expression plasmid as a cell number control, and either one of the expression plasmids for the ERs. The fold-change in luciferase expression over renilla expression in treated vs untreated controls was used to determine transcriptional activity. Of the oxysterols tested, only 27-OHC inhibited the transcriptional activity of both receptors at 10 mM [ Fig. 2 and Fig. 3(A) ]. 24(S)-OHC significantly inhibited ERb transcriptional activity only at the highest dose tested [ Fig. 3(C) ].
Full-dose curves for 27-OHC and 24(S)-OHC were then performed to obtain IC50s via analysis with Prism 6.0 software (GraphPad). 27-OHC is an antagonist for both receptors, but 27-OHC inhibited ERb with better potency than it did ERa [ Fig. 4 (A) and 4(B)]. Also of note is that (similar to the binding observations) saturating concentrations of 27-OHC inhibited ERb to only ;35% of maximum stimulated activity. For ERa, 27-OHC had an IC50 . 2 mM [Fig. 4(A) ]. However, for ERb, 27-OHC had an IC50 of ;130 nM in the Ishikawa cell line [ Fig.  4(B) ]. 27-OHC is a selective ERb antagonist that displays .10-fold selectivity over ERa in this assay. Similar results for 27-OHC were also obtained in the C4-12-5 cell line (Supplemental Fig. 2) .
The full dose curve of 24(S)-OHC confirmed that inhibition was only observed at the highest dose tested (10 mM) for ERb [Supplemental Fig. 1(B) ]. Despite the interesting observation that 24(S)-OHC inhibited E2 binding to ERb to a maximum of 50%, the Ki of 170 nM is at the upper limits of physiological relevance for this oxysterol, and it did not have a corresponding effect in our activity assay (26, 27) . For these reasons, we decided to focus on 27-OHC. Examining the incomplete inhibition of E2 binding to ERb by 27-OHC 27-OHC binding effects are on the specific binding of the receptor. The nonspecific binding did not significantly increase in the presence of high concentrations of 27-OHC, ruling out the possibility of a simple artifact caused by a lack of sufficient adsorption by the dextran-coated charcoal (Supplemental Fig. 3 ). We also analyzed the ability of 27-OHC to form micelles, which would limit its effective concentration, using a dye incorporation assay, and found no evidence of a critical micellar concentration from 0.1 to 30 mM (Supplemental Fig. 4 ). However, it was noted that adding 27-OHC to final concentrations of 100 to 150 mM, in assay buffer, caused the solution to become homogeneously opaque, and concentrations of $300mM were visibly insoluble. For this reason, we chose to use no higher than 30 mM in our experiments.
Multiple competition experiments were performed at various doses of fixed 3 H-E2 to determine the effect of E2 concentration on the resulting competition curves of 27-OHC. Strikingly, across a 30-fold range of 3 H-E2 concentrations, the maximum binding inhibition observed at saturating concentrations of 27-OHC decreased from ;90% to 25% whereas the IC50s were shifted less than threefold [Supplemental Fig. 5(A)-5(D) ]. These data offer additional evidence against the possibility of 27-OHC being a competitive ligand that is merely solubility limited. If it were, it would inhibit binding competitively until it hits its solubility point (or critical micellar concentration), after which any additional ligand would not be available for binding: that is, any higher concentrations tested would show no additional influence on the binding of the tracer. Although our curves do mostly begin to bottom out at ;3 mM, the 10-mM and 30-mM concentrations almost always further inhibit binding [Supplemental Fig. 5(A)-5(C) ].
27-OHC is a negative allosteric modulator of E2 binding to ERb
The above evidence clearly demonstrated that 27-OHC was not a classically competitive ligand with E2 for binding to ERb, nor were the unique curves the result of various artifacts. We hypothesized that the lack of complete competition was the result of allosteric, rather than competitive, binding. Running an allosteric binding analysis on our original binding data from Fig. 1(B) , in GraphPad we obtained a Ki of 35 nM for 27-OHC and a cooperativity factor (a) of 0.029. We used a standard allosteric ternary complex model to obtain theoretical equilibrium dissociation constant (Kd)/Ki values for all possible receptor-ligand combinations. This predicts that when the receptor is saturated by both E2 and 27-OHC, each would have an apparent Kd or Ki that was shifted ;30-fold, ;5 nM, and ;1 mM, respectively (Fig. 5) .
To test our model, we created an affinity ratio plot, which is a classic diagnostic plot for negative allosteric modifiers (44, 45) . The affinity ratio plot was constructed from the results of multiple saturation binding assays. Each saturation binding assay was done in the presence of various doses of a fixed concentration of 27-OHC to determine its effect on tritiated E2 saturation binding. Across a 1000-fold range of 27-OHC concentrations, the apparent Kd (KdApp) of E2 only increased to a maximum of 4.4 nM (Fig. 6, insert) .
On a standard affinity ratio plot, a strictly competitive ligand will give a straight line when plotted as log
Negative allosteric modifiers will yield a curved line with a horizontal asymptote related to the value of a, and x-intercept related to the Ki, when plotted this way. In Fig. 6 , the dotted line is an idealized strictly competitive ligand with Kd = 35 nM. The dashed line is an idealized allosteric modifier with our values from our allosteric analysis of Fig. 1(B) . The solid line is the best-fit line using nonlinear regression with the formula above and our actual KdApp values experimentally determined from the saturation analyses. Taken together, these experiments give strong evidence that 27-OHC is a negative allosteric modifier of E2 binding to ERb with an a of 0.036 and a Ki of 50 nM (Fig. 7) . Figure 6 also strengthens the argument against 27-OHC being solubility limited. 27-OHC at 300 nM, which is well within observed physiological concentrations and below any suspected solubility point, demonstrates an allosteric effect rather than competitive on the apparent Kd of 3 H-E2 in saturation assays (Fig. 6) . If 27-OHC were a solubility limited competitor, any concentration below the solubility point would act competitively and lie along the dotted red (competitive) line in Fig. 6 , not the dashed red or solid black lines (allosteric). Additionally, 30 mM 27HC inhibits the apparent Kd of E2 by ;16% more than 3 mM in these assays (Fig. 6, insert) .
Docking of 27-OHC and E2 in the 3D structure of ERb Using in silico docking, we assessed the ability of 27-OHC and E2 to bind in the canonical E2 binding site as well as an alternative site near the small b sheet within the ligand binding pocket of ERb (PDB: 3OLS). Rosetta ligand, running on the Rosetta Online Server that Includes Everyone, was used to search a 5A radius centered within the canonical site and a 4.5A area centered near the b strands. Interestingly, 27-OHC could not be docked successfully within the alternate site, but E2 could [ Fig. 8(A) and 8(B) ]. It appears that the D rings of two E2 molecules would overlap if they were both in the pocket at the same time. However, 27-OHC and E2 may fit together, as 27-OHC sits relatively higher in the pocket and its tail extends through the area where the D ring of E2 would be in the canonical site, allowing more space for E2 in the alternate site. There are relatively few conflicting residues when the two models are overlaid, and the only conflict between the two ligands is between the D ring hydroxyl of E2 and the flexible side chain of 27-OHC [ Fig. 8(C) ].
Discussion
As a negative allosteric modifier, 27-OHC allows for a unique fine-tuning of ERb binding and activity. With respect to its antagonistic response activity, it does not inhibit activity to baseline, with an appearance similar to that of a partial agonist. However, we have shown here that this effect is more likely due to its ability to bind ERb simultaneously along with E2 and allosterically induce a conformational change in the receptor that reduces the receptor's affinity for E2. This is different from a classical partial agonist, which binds competitively with a full agonist but does not stimulate to the same extent.
We have been able to explain our ERb binding data via the use of a standard allosteric ternary complex model. There are many reasons why our data may differ from a previous report (22) . In that report, the authors chose to use concentrations of hot E2 that were only ;twofold higher than the Kd, and we used concentrations that were ;15-fold higher than our Kd in our initial assays. Our data with various doses of hot E2 clearly show how this affects the observed binding curves, with lower doses yielding curves that appear more like competitive ligands. It is also important to note that the reported total binding in that report is more than the recommended 15% of the total hot E2, which leads to ligand depletion. If the binding is not allosteric, a reasonable amount of ligand depletion can be easily corrected for, so this would not be a major concern. However, ligand depletion has larger and unexpected effects on the binding constants obtained when the unlabeled ligand is an allosteric modifier (46) .
We cannot, however, so easily explain the differences obtained with 27-OHC binding to ERa. Certainly, the previously mentioned factors apply, but we would still expect to see some inhibition of binding at the concentrations of hot E2 and 27-OHC tested here if 27-OHC had equal effects on each receptor. In preliminary studies, we saw a small amount of inhibition of 1 nM hot E2 binding to ERa, but it was not enough to accurately determine binding constants. It is possible that 27-OHC binds ERa allosterically as well but has a combination of poorer affinity and allosteric effect (a), relative to ERb, such that technically it cannot be measured unless very low hot E2, and very high 27-OHC concentrations are used. The present study demonstrates simultaneous binding of two endogenous ligands to the ER. Previous reports of alternate binding sites in other nuclear receptors include androgen receptor (47, 48) , thyroid hormone receptor (49, 50) , vitamin D receptor (51, 52) , and peroxisome proliferatoractivated receptor g (53, 54). There have also been previous reports of exogenous ligands binding to alternate sites within ERa and ERb (55) (56) (57) . Trilostane (a synthetic 3b-hydroxysteroid dehydrogenase inhibitor) was previously reported to be a positive allosteric modulator of E2 binding and a noncompetitive inhibitor of ER function (58) . The alternate site in our 3D model is in the same relative location as that proposed by Mizwicki et al. (52) , as well as the recently identified alternate binding site in peroxisome proliferator-activated receptor g (53). Our 3D model is an intriguing starting point, yet many questions remain. It appears in this model that 27-OHC should be able to be completely competed off by E2, but that does not fit with our data. The model we used is based on the structure of the ERb ligand binding domain in the presence of E2, and the structure may be very different in the presence of 27-OHC because there is a great deal of plasticity in the ligand binding pockets of nuclear receptors, including the ERs (59). It may also be possible that competition is less likely because of the two molecules stabilizing each other in the positions modeled, similar to the recent observation in pregnane X receptor (60) .
Recently, we have shown that mice lacking ERb have a higher incidence of advanced prostate cancer in the TRAMP mouse model (13) . The ERb-selective agonist 8b-VE2 has been shown to cause apoptosis in prostate cancer cells in vitro (15) . Because of the high affinity of 27-OHC, we speculate that this may be an important biomarker for the success of treating prostate cancer with ERb-selective agonists, such as 8b-VE2, in vivo. Those with hypercholesterolemia may be at a higher risk because 27-OHC concentrations are positively correlated with those of total cholesterol, and this has recently been demonstrated in breast cancer (25, 61, 62) . In addition, because total cholesterol, and thus 27-OHC, increases with age, we believe this may be a factor in the increased incidence of prostate cancer in the aging population. Interestingly, in patients with prostate cancer, a decrease of CYP27A1 (the enzyme that makes 27-OHC) is associated with increased recurrence and grade in prostate cancer (63) .
The status and interplay among LXRs, ERs, and 27-OHC metabolizing enzymes will probably be of great importance to our understanding of estrogen-responsive processes. We hypothesize that 27-OHC will have a substantial impact in many cases where ERb agonists are used for their positive biological effects. Several ERbselective agonists have been tested for their ability to inhibit disease processes, ranging from inflammatory diseases to cancer, but these have not experienced the success in humans that they have preclinically (9, 10, 64, 65) . In conclusion, 27-OHC is an ERb-selective negative allosteric modulator of 17b-estradiol binding. Structural and mutational studies are needed to confirm the site of 27-OHC binding in the presence and absence of E2. 27-OHC's potentially important role as a biomarker, investigational agent, and drug target in many disease processes warrants continued study. 
